国际标准期刊号: 2167-065X

临床药理学与生物药剂学

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • CAS 来源索引 (CASSI)
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • Genamics 期刊搜索
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • 普布隆斯
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Reishi (Ganoderma lucidum): A Potential Source of Nutraceuticals and Prebiotics

Sandeep Singh Bhadoriya, Prashant Wadagbalkar, Praveen Sharma, Sachin Kumar Jain

Background: In Asian nations, Ganoderma lucidum, often known as lingzhi, has been used to generally promote health and lifespan. With high-quality proteins, amino acids, nucleosides, vitamins, critical minerals, and dietary fibres (quitin, polysaccharides), Ganoderma lucidum is a highly nutritious, low-calorie food. A significant and underutilised source of nutraceuticals and prebiotics is Ganoderma lucidum.

The development of mushrooms is beneficial to the food, pharmaceutical, and nutraceuticals industries in developing nations like China, Japan, Korea, and India. Ganoderma lucidum has long been regarded as the best nutritious meal for obese people and for diabetics to prevent hyperglycemia due to its high fibre, low fat, and low starch content. It is mostly made up of dietary fibres and polysaccharides that encourage the growth of good bacteria. It is mostly made up of dietary fibres and polysaccharides that encourage the formation of good bacteria in the digestive tract. They are maintaining intestinal health, preventing cancer, enhancing immunity, lowering cholesterol, and preventing obesity, among other positive effects. Its potential as a nutraceutical and prebiotic is attributed to the presence of a wide range of phytoconstituents, including tocopherols, phenolics, flavonoids, carotenoids, dietary fibres, ascorbic acid, selenium, germanium, luecine, lysine, adenosine, and uracil. There is no proof of liver, kidney, or DNA toxicity with consumption of Linngzhi, according to the toxicity study on human clinical trial.

Present overview: The current research highlights the urgent need for the scientific community to promote Ganoderma lucidum as a potential source of nutraceutical and prebiotic products. To characterise the active component (s) of this alleged medicinal mushroom, as well as to discover mechanisms of action, techniques for improving quality control systems are required to define and standardise G. lucidum formulations. The current review will result in a new generation of foods and will undoubtedly encourage both their dietary and therapeutic benefits.

Graphical Abstract